

## **Version 2**

**Title:** No association between the SARS-CoV-2 variants and mortality rates in the Eastern Mediterranean Region

**Authors:** Saad Omais<sup>1</sup>, Samer Kharroubi<sup>2</sup>, Hassan Zaraket<sup>3,4,#</sup>

### **Affiliations:**

1, Department of Biology, Faculty of Arts and Sciences, American University of Beirut, Beirut, Lebanon.

2, Department of Nutrition and Food Sciences, Faculty of Agricultural and Food Sciences, American University of Beirut, Beirut, Lebanon.

3, Faculty of Medicine, Center for Infectious Diseases Research, American University of Beirut, 1107 2020 Beirut, Lebanon.

4, Department of Experimental Pathology, Faculty of Medicine, Immunology & Microbiology, American University of Beirut, 1107 2020 Beirut, Lebanon.

**# Corresponding author:** [hz34@aub.edu.lb](mailto:hz34@aub.edu.lb)

**# Present/permanent address:** Department of Experimental Pathology, Faculty of Medicine, Immunology & Microbiology, American University of Beirut, 1107 2020 Beirut, Lebanon

**Keywords:** SARS-CoV-2, whole genome, variants, case fatality rate, East Mediterranean Region

1 **Abstract**

2 As the novel coronavirus SARS-CoV-2 continues to spread in all countries, there is a growing  
3 interest in monitoring and understanding the impact of emerging strains on virus transmission  
4 and disease severity. Here, we analyzed SARS-CoV-2 genomic sequences reported in the  
5 Eastern Mediterranean Region (EMR) countries, as of 1 January 2021. The majority (~75%) of  
6 these sequences originated from three out of 22 EMR countries, and 65.8% of all sequences  
7 belonged to GISAID clades GR, GH, G and GV. A delay ranging between 30-150 days from  
8 sample collection to sequence submission was observed across all countries, limiting the utility  
9 of such data in informing public health policies. We identified ten common non-synonymous  
10 mutations represented among SARS-CoV-2 in the EMR and several country-specific ones. Two  
11 substitutions, spike\_D614G and NSP12\_P323L, were predominantly concurrent in most  
12 countries. While the single incidence of NSP12\_P323L was positively correlated with higher  
13 case fatality rates in EMR, no such association was established for the double (spike\_D614G and  
14 NSP12\_P323L) concurrent variant across the region. Our study identified critical data gaps in  
15 EMR highlighting the importance of enhancing surveillance and sequencing capacities in the  
16 region.

## 17 **Introduction**

18 In early October 2020, the World Health Organization (WHO) estimated that 10% of the global  
19 population has been infected with the novel coronavirus, SARS-CoV-2 ([Keaten, 2020](#)). Since its  
20 declaration as a pandemic seven months earlier, COVID-19 has inflicted substantial health and  
21 economic burden around the world ([Fineberg, 2020](#); [Ioannidis, 2020a](#)). As of 22 January 2021,  
22 there have been over 96 million confirmed cases and 2 million deaths attributed to COVID-19  
23 ([WHO](#)). Specifically, 5,461,398 confirmed cases (of whom 4,815,552 have recovered) and  
24 130,079 deaths were reported in the Eastern Mediterranean Region (EMR) ([WHO](#)).

25 Prior to SARS-CoV-2 emergence, six human coronavirus (HCoV) strains were known to infect  
26 humans: two of which caused fatal respiratory diseases (SARS-CoV-1 and MERS-CoV), while  
27 the remaining four circulate annually and cause 15-29% of all common colds (HCoV-229E, -  
28 OC43, -NL63 and -HKU1) ([Su et al., 2016](#)). SARS-CoV-2 gains access to the host cell by  
29 binding to the human angiotensin-converting enzyme 2 (hACE2) through its spike (S) protein.  
30 SARS-CoV-2 S receptor-binding domain (RBD) has a 10- to 20-fold higher hACE2 binding  
31 affinity than SARS-CoV-1 ([Wrapp et al., 2020](#)). Yet, SARS-CoV-2 RBD is less accessible such  
32 that the overall S-hACE2 interaction is similar or weaker than that of SARS-CoV-1.  
33 Nonetheless, the SARS-CoV-2 spike protein possesses a polybasic cleavage site making it  
34 accessible to furin protease which enhances cell entry ([Shang et al., 2020](#)). Similar to other beta-  
35 coronaviruses, SARS-CoV-2 has a positive-sense RNA genome that is around 30-kb in length  
36 with six functional open reading frames (ORFs). ORFa and -b constitute nearly two-thirds of the  
37 genome and produce 16 non-structural proteins (NSPs), including the RNA-dependent RNA  
38 polymerase (RdRp or NSP12) and a helicase (NSP13). The structural nucleocapsid (N),

39 membrane (M), envelope (E), and S proteins are encoded by the remaining stretch of the RNA  
40 genome along with other accessory proteins ([Hartenian et al., 2020](#)).

41 There has been a tremendous global surveillance effort to closely monitor SARS-CoV-2  
42 circulating worldwide that enabled timely detection of emerging variants. SARS-CoV-2 evolves  
43 at an estimated rate of around  $6 \times 10^{-4}$  nucleotides/genome/year ([van Dorp et al., 2020a](#)).  
44 Numerous variants have emerged but only a handful of them have been fixated such as the  
45 S\_D614G that has prevailed globally. S\_D614G was shown to alter infectivity and virulence of  
46 SARS-CoV-2 and was associated with an increase in mortality ([Eaaswarkhanth et al., 2020](#);  
47 [Plante et al., 2020](#); [van Dorp et al., 2020a](#); [Vankadari, 2020](#); [Wang et al., 2020](#)). Specifically,  
48 Sallam et al. reported an increase in the incidence of S\_D614G variant between February and  
49 June 2020 in the Middle East and North Africa ([Sallam et al., 2021](#)). However, a detailed  
50 genomic characterization of SARS-CoV-2 in EMR is still lacking. It also remains not clear  
51 whether the case fatality rates (CFRs) in EMR are associated with any of the prevailing SARS-  
52 CoV-2 variants. In this study, we analyzed SARS-CoV-2 whole-genome sequences collected in  
53 EMR and examined the temporal and country-level associations between the predominant  
54 variants and CFRs.

## 55 **Methods**

### 56 *Sequence Retrieval and Analysis*

57 SARS-CoV-2 sequences were downloaded from GISAID EpiCoV™ database ([Shu and](#)  
58 [McCauley, 2017](#)) which were submitted by 1 January 2021 from EMR countries. These are  
59 Afghanistan, Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco,  
60 Oman, Pakistan, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syrian Arab Republic, Tunisia,

61 United Arab Emirates (UAE), and Yemen (<http://www.emro.who.int/countries.html>). Only ‘high  
62 coverage’ sequences were selected, i.e. “entries with <1% Ns and <0.05% unique amino acid  
63 mutations (not seen in other sequences in the database) and no insertion/deletion unless verified  
64 by submitter”. These were then analyzed by CoVsurver enabled by GISAID  
65 (<https://www.gisaid.org/epiflu-applications/covsurver-mutations-app/>) and compared with  
66 reference strain hCoV-19/Wuhan/WIV04/2019 (accession number: EPI\_ISL\_402124). Sequence  
67 metadata corresponding to age and gender were extracted from EpiCoV™ ‘nextmeta’ file for  
68 sequences submitted as of 12 November 2020. For clade analysis, we used the Nextclade tool  
69 from the Nextstrain project (<https://clades.nextstrain.org/>) ([Hadfield et al., 2018](#)) and GISAID  
70 clade designation provided by CoVsurver analysis.

#### 71 *Country Data and Mortality Rate*

72 Data on population size, total COVID-19 cases, and total deaths were retrieved from the  
73 Worldometers website as of 22 January 2021 (<https://www.worldometers.info/coronavirus/>).  
74 Data on daily cases and deaths per country were extracted from WHO Coronavirus Disease  
75 (COVID-19) Dashboard (<https://covid19.who.int/>) ([WHO](#)). CFR was calculated and adjusted for  
76 a 13-day lag time from reporting to death, such that the denominator was designated as the  
77 cumulative cases from 13 days earlier, while the numerator totaled the cumulative deaths till 13  
78 days earlier plus half the additional deaths recorded during the lag period ([Wilson et al., 2020](#)).

#### 79 *Statistical Analysis*

80 The data were checked for completeness and entered into the Statistical Package for the Social  
81 Sciences (SPSS) software version 20 for Windows, which was later used for statistical analyses  
82 [IBM: Statistical Package for the Social Sciences. SPSS Statistics 2013, 20.]. Eight of the 15

83 EMR countries that have sequence data available were excluded from cross-country fatality  
84 correlations for the following reasons: Egypt had a relatively high CFR (5.9%) probably as a  
85 result of the low number of reported cases (1073 cases per million) likely due to limited testing  
86 capacity; Iraq, Pakistan, Tunisia, Lebanon, Kuwait, and Qatar had a relatively low sequence  
87 count each (<50, 1.5% of all sequences) (**Figure 1A**), Iran had only 18 complete sequences (>25  
88 kbp) out of 104 sequences and was thus less comparable to other sequences (**Supplementary**  
89 **Figure 1**). For the summary of the data, descriptive statistics were presented to summarize the  
90 study variables of interest as counts and percentages across countries. Pie charts and bar plots  
91 were used to chart comparison in count and percentages of variants across all countries. An  
92 independent t-test was used to chart the comparison of variants via gender (male vs female),  
93 while one-way ANOVA was carried out for age distribution (0-9, 10-18, 19-49, 50-59, and >60).  
94 Pearson's correlation coefficients were used to examine the association between variant  
95 percentages and CFR for the seven countries considered in this study ([Toyoshima et al., 2020](#)).  
96 For all analyses done, a *p-value* of less than 0.05 was used to detect statistical significance.

## 97 **Results**

98 We identified 3345 high-coverage SARS-CoV-2 genome sequences from EMR countries – no  
99 sequences were available for Afghanistan, Djibouti, Libya, Somalia, Sudan, Syria, and Yemen.  
100 Three countries accounted for ~75% of the sequence count overall – UAE (n=1233), Saudi  
101 Arabia (n=762) and Jordan (n=512) (**Figure 1A**). All but 5 EMR countries – Iran, Tunisia, Iraq,  
102 Pakistan and Kuwait – had near-full length sequences of SARS-CoV-2 (**Supplementary Figure**  
103 **1**). UAE had the highest sequence to population ratio (123.8 in 1 million), but also the highest  
104 number of sequences per reported COVID-19 cases (45.5 per 10,000 cases) (**Figure 1B, 1C**).  
105 When dates of collection were considered, none of the countries showed routine and consistent

106 sequencing; most sequences were collected before July (e.g. from UAE, Saudi Arabia, Oman)  
107 while only few countries (mainly Jordan, Bahrain and Morocco) reported sequences from the last  
108 three months (**Figure 1D**). Moreover, a significant delay between sample collection and  
109 sequence submission was observed across all countries (ranging 30-150 days), with no  
110 noticeable progress between first and last 100 days for the top three represented countries  
111 (**Figure 1E**).

112 Using CoVsurver from GISAID, amino acid substitutions were identified in each viral protein  
113 sequence and the top ten prevalent variants for each country were then plotted (excluding single-  
114 incidence variants) (**Figure 2**). In total, 2155 non-synonymous mutations were detected in EMR  
115 countries, out of which ten common variants were found to be relatively most common (i.e. in  $\geq$   
116 8 EMR countries and  $> 2.5\%$  of all sequences). These are: NSP12\_P323L, S\_D614G,  
117 NS3\_Q57H, N\_R203K, N\_G204R, N\_S194L, NSP6\_L37F, NSP2\_V198L, NS8\_L84S and  
118 N\_S202N. Besides, many country-specific substitutions were detected (here defined as found in  
119 3 other countries or less, and not listed in other countries' most common mutations). For  
120 instance, NSP3\_V1209I was found in 18% of UAE's sequences, Spike\_Q957L in 80% of  
121 Jordan's sequences and NSP12\_M666I in 76% of Palestine's sequences (**Figure 2**).  
122 NSP12\_P323L and S\_D614G were predominantly detected in 10 out of 15 countries. S\_D614G  
123 was also dominant in Bahrain. In Kuwait and Iran, NSP6\_L37F and NSP2\_V198L were the most  
124 frequently reported variants.

125 Next, we used the Nextclade tool from Nextstrain to assign clades (GISAID nomenclature) to the  
126 sequences (**Figure 3A**) ([GISAID, 2020](#)). Of all sequences from EMR countries, 65.8% belonged  
127 to the G (20A per Nextstrain clades), GR (20B), GH (20C) and GV (20A.EU1) clades, which  
128 emerged following the introduction of the S\_D614G variant (**Figure 3B**, ([Alm et al., 2020](#))).

129 Moreover, these clades were almost exclusively represented as early as February and March in  
130 Saudi Arabia. In UAE, Jordan and Oman, clade distribution was heterogeneous with multiple  
131 clades cocirculating between February through November (**Figure 3C**).

132 For the sequence cohort submitted by 12 November 2020, more specimens were sequenced from  
133 males in the EMR (2.05:1 male-to-female in top four represented countries, independent t-test  $p$   
134  $< 0.004$ ): Saudi Arabia (4.44:1), UAE (2.25:1), Oman (1.42:1) and Egypt (1.49:1) (**Figure 4A**).  
135 No statistically significant difference in gender distribution of the top represented SARS-CoV-2  
136 variants were observed in these countries (independent t-test for all variants,  $p > 0.270$ ) (**Figure**  
137 **4B**). By analyzing the age distribution of the top variants in these countries, we observed a  
138 statistically significant underrepresentation in the number of sequenced viruses from children (0-  
139 9 years) ( $3.43\% \pm 1.21$  S.E.M.) and young adolescents (10-18 years) ( $2.26\% \pm 1.16$ ), while  
140 adults (19-49) were more represented ( $62.5\% \pm 8.84$ ) (ANOVA;  $F = 73.4$ ,  $p = 1.15E-9$ ) (**Figure**  
141 **4C**). For the three remaining age categories (19-49, 50-59 and  $>60$  years), we report no  
142 statistically significant difference in the occurrence of the Wuhan-like or any of the identified  
143 variants (multivariate ANOVA for all variants,  $F < 0.906$ ,  $p > 0.487$ ) (**Figure 4D**).

144 We next sought to determine whether a correlation exists between the incidence of the ten most  
145 common variants and countries' CFRs. Only seven countries were included in this analysis –  
146 UAE, Saudi Arabia, Jordan, Oman, Bahrain, Palestine and Morocco – where only NSP12\_P323L  
147 out of the ten variants was significantly correlated with an increase in CFR ( $R=0.883$ ,  $P=0.008$ )  
148 (**Figure 5**). However, consistent with previous studies ([Ilmjärv et al., 2020](#); [Kannan et al., 2020](#)),  
149 we confirm that NSP12\_P323L seems to have quickly co-evolved following S\_D614G  
150 introduction, as they are more often co-detected among SARS-CoV-2 genome sequences  
151 (**Figure 6A**). This double variant 'D614G & P323L' is found to be evenly represented among



152 different age groups in UAE, Saudi Arabia, Oman and Egypt (for sequences submitted by 12  
153 November) (**Figure 6B**). After repeating the correlation analysis while accounting for the single  
154 versus double occurrence of D614G and P323L, we found that neither single nor double variants  
155 were significantly correlated with CFR. The P323L-single variant was mainly detected in Saudi  
156 Arabia (19% of its sequences) and among 0.5% sequences reported from UAE, while in the other  
157 countries it was exclusively co-detected with D614G. As such, we suggest that the earlier  
158 correlation of NSP12 P323L is likely the result of considering single- and double-variants as one  
159 group, specifically in Saudi Arabia. However, when such distinction was made, no correlation  
160 with higher CFR was reported in either group (**Figure 6C**).

161 Since sequences of UAE, Saudi Arabia and Oman were dominantly collected before September  
162 and those of Jordan and Bahrain were collected afterwards (**Figure 1D**), we repeated our  
163 analysis but this time accounting for the cumulative incidence of the 'D614G & P323L' double  
164 variant and the CFR at the end of each month. We observed no significant association between  
165 these two variables from March through September (**Supplementary Figure 2**). To further  
166 investigate this correlation, we considered the cumulative monthly incidence of 'D614G &  
167 P323L' and the monthly CFRs (**Figure 7A**): while UAE showed a significantly negative  
168 correlation between 'D614G & P323L' incidence and the monthly CFR ( $R=-0.830$ ,  $P=0.021$ ),  
169 Saudi Arabia showed a significantly positive correlation ( $R=0.909$ ,  $P=0.012$ ). Meanwhile, Jordan  
170 and Oman had no significant associations ( $R=-0.101$ ,  $P=0.849$ ;  $R=0.921$ ,  $P=0.079$  respectively)  
171 (**Figure 7B**). This suggests that by accounting for the change in CFR for each country with time  
172 the correlation between 'D614G & P323L' incidence and higher fatality does not necessarily  
173 hold true contrary to previous findings ([Becerra-Flores and Cardozo, 2020](#); [Eaaswarkhanth et al.,  
174 2020](#); [Toyoshima et al., 2020](#)).

## 175 **Discussion**

176 In this study, we analyzed whole-genome sequences of SARS-CoV-2 collected in the EMR  
177 countries. Significant data gaps are notable, whereby sequences were lacking for seven EMR  
178 countries – the majority of which are in war conflict zones (e.g., Syria, Libya, and Yemen ([Daw,  
179 2020](#))). In general, large disparities in the availability of sequences are observed across EMR.  
180 Only five countries reported  $\geq 150$  sequences spanning the first year of the pandemic, with UAE,  
181 Saudi Arabia and Jordan exceeding 500 sequence submissions. These data gaps highlight the  
182 challenges for monitoring the pandemic in developing countries particularly in conflict zones. It  
183 also emphasizes the importance of building regional sequencing capacities for timely and  
184 continuous monitoring of viral evolution during the pandemic ([Al Saidi et al., 2020](#); [Salameh,  
185 2020](#)).

186 Despite the diversity in the substitutions detected across countries, only a handful of variants  
187 predominated. For instance, a mere 9 out of 945 non-synonymous mutations (0.95%) in UAE  
188 and 6 out of 421 mutations (1.4%) in Saudi Arabia were detected in more than 10% of the  
189 respective total of sequences (**Figure 2**). This suggests that consistent with other studies, most  
190 SARS-CoV-2 mutations are neutral or deleterious ([van Dorp et al., 2020a](#)). Although a random  
191 founder's effect cannot be ruled out, the increased frequency of certain substitutions might be  
192 attributable to a fitness advantage ([Callaway, 2020](#); [Grubaugh et al., 2020](#); [Kannan et al., 2020](#);  
193 [Plante et al., 2020](#); [Yurkovetskiy et al., 2020](#); [Zhang et al., 2020](#)). For instance, the S\_D614G  
194 was found to predominate all viral strains globally (78% of sequences by May 2020) and was  
195 associated with increased viral loads in the upper respiratory tract of COVID-19 patients ([Korber  
196 et al., 2020](#)). Along the same line, Plante et al. recently demonstrated that S\_D614G enhanced  
197 viral replication and infectivity of SARS-CoV-2 in human lung epithelial cells and primary

198 human airway tissues and increased infectious virus loads in hamsters' nasal cavities ([Plante et](#)  
199 [al., 2020](#)). Hou et al. further showed that the S\_D614G variant displayed faster transmission and  
200 increased competitive fitness *in vivo* compared to wild-type virus in hamsters ([Hou et al., 2020](#)).  
201 These findings were also confirmed in hACE2 knock-in mice as well as in ferrets ([Zhou et al.,](#)  
202 [2021](#)). On a molecular level, S\_D614G allows for more efficient infectivity by shifting the spike  
203 protein to a more 'open' conformation that is more favorable of ACE2 binding ([Yurkovetskiy et](#)  
204 [al., 2020](#)). Interestingly, however, a recent analysis by van Dorp et al. could not identify any  
205 single recurrent mutation, including the S\_D614G, to be convincingly associated with increased  
206 viral transmission in humans ([van Dorp et al., 2020b](#)).

207 Several studies reported a positive correlation between S\_D614G incidence and mortality (CFR)  
208 ([Becerra-Flores and Cardozo, 2020](#); [Eaaswarkhanth et al., 2020](#); [Toyoshima et al., 2020](#)).  
209 However, a more recent study of 25,000 SARS-CoV-2 sequences in the United Kingdom did not  
210 associate the incidence of this mutation with higher COVID-19 mortality or with clinical severity  
211 in patients ([Volz et al., 2021](#)). Similarly, Korber et al. did not find an association between  
212 S\_D614G and increased disease severity or hospitalization ([Korber et al., 2020](#)). In our sequence  
213 set, we saw no association between S\_D614G with CFRs of select EMR countries. Instead, the  
214 increasing incidence of NSP12\_P323L (of the ten most common substitutions), when considered  
215 alone, was correlated with a higher mortality rate. However, our data as well as others' ([Ilmjärvi](#)  
216 [et al., 2020](#); [Kannan et al., 2020](#)) show that the NSP12\_P323L and S\_D614G are frequently  
217 coupled in most sequences, suggesting co-evolution of these variants (**Figure 6A**). Therefore, we  
218 assessed the combined effect of the 'D614G & P323L' double variant on mortality. We found no  
219 correlation between the cumulative incidence of the 'D614G & P323L' variant and CFRs in the  
220 EMR countries, consistent with earlier observations that found no association between 'D614G

221 & P323L' and deaths per million, CFR and patient status ([Ilmjärv et al., 2020](#)). In contrast to the  
222 well-studied S\_D614G, the effect of NSP12\_P323L on viral fitness is much less understood  
223 ([Hillen et al., 2020](#); [Pachetti et al., 2020](#)). One study speculated that it negatively impacts NSP8's  
224 association with RdRp leading to an attenuated polymerase activity ([Ilmjärv et al., 2020](#)), while  
225 another suggested that it enhances hydrophobic NSP8-RdRp interactions leading to improved  
226 processivity of RdRp and enhanced viral replication overall ([Kannan et al., 2020](#)). In all cases, it  
227 is speculated that the 'epidemiological success' of the G, GH, GR and GV lineages could be  
228 attributed to the combined viral fitness advantage conferred by both NSP12\_P323L and  
229 S\_D614G ([Ilmjärv et al., 2020](#)).

230 Considering the limitations due to the discrepant number of sequences available (as mentioned  
231 above) or to country-specific variations in managing the COVID-19 pandemic (such as testing  
232 capacity, age stratification, enforcing/relaxing lockdown policies, etc.), we assessed the  
233 association of 'D614G & P323L' incidence with CFR within each of the top four represented  
234 countries over time. Interestingly, we found a significantly negative correlation between 'D614G  
235 & P323L' incidence and COVID-19 CFR in UAE, but an otherwise positive correlation in Saudi  
236 Arabia (**Figure 7B**). This suggests that the reported correlation between these variants and  
237 increased CFR might be a mere coincidence rather than true causation. Noteworthy, our method  
238 of calculating daily/monthly CFR is credited for accounting for a 13-day lag between cumulative  
239 cases and deaths ([Wilson et al., 2020](#)). Yet, it overestimates the case fatality risk early on in the  
240 pandemic ([Ge and Sun, 2020](#)), a limitation that would apply to our final analysis. Then again,  
241 considering the overwhelming discrepancy in fatality correlations between countries, it is  
242 unlikely that early bias in CFR estimation would have altered our conclusion. Additionally, a  
243 more accurate method to estimate COVID-19 mortality would be the infection fatality rate (IFR),

244 inferred from seroprevalence studies. However, such data is only available for Iran, Pakistan, and  
245 Qatar out of all EMR countries according to a recent WHO review ([Ioannidis, 2020b](#)).

246 Other genomic mutations were associated with milder disease, such as a major deletion ( $\Delta$ 382;  
247 nucleotide positions: 27,848 to 28,229), which results in truncated ORF7b and arrested  
248 transcription of ORF8 ([Su et al., 2020](#)). Patients infected with the SARS-CoV-2  $\Delta$ 382 variant  
249 had less systemic release of proinflammatory cytokines and better clinical outcomes (i.e. lower  
250 frequency of hypoxia requiring supplemental oxygen) than wild-type ([Young et al., 2020](#)). This  
251 variant, however, was not present in any of our sequence cohort. Moreover, an S\_ N439K variant  
252 was reported to enhance spike binding to its protein hACE2, resulting in immune escape from a  
253 panel of neutralizing monoclonal antibodies ([Thomson et al., 2021](#)). We detected only one  
254 sequence carrying this mutation from Morocco (EPI\_ISL\_728353).

255 On a final note, the COVID-19 pandemic cannot be viewed in the absence of other respiratory  
256 viruses, especially in view of the increased concerns regarding a ‘Twindemic’ ([Uyeki et al.,  
257 2020](#); [Adlhoch et al., 2021](#)). In the case of influenza, few cases were reported in EMR countries  
258 in 2020-21 season (<20 positive specimens per week; GISRS report ), a pattern that was  
259 established worldwide ([Jones, 2020](#)). Previous studies from the United States and Australia  
260 reported a co-infection rate ranging from 2% to 6.9% between SARS-CoV-2 and other  
261 respiratory viruses including rhinovirus/enterovirus, RSV, other coronaviruses, and influenza  
262 virus ([Kim et al., 2020](#); [Kim et al., 2021](#)). Elghoudi et al. reported an incidence of 3.1% (9/288)  
263 respiratory co-infections with SARS-CoV-2 in children and young adolescents in a hospital in  
264 UAE ([Elghoudi et al., 2020](#)). In addition to co-infections with respiratory viruses a study from  
265 Pakistan reported a relatively high incidence of co-infections between SARS-CoV-2 and the  
266 endemic dengue virus – 25% (5/20) of studied samples ([Saddique et al., 2020](#)). A meta-analysis

267 study estimated that while 3% of COVID-19 patients (out of 1014 patients from 16 studies) had a  
268 confirmed viral co-infection, there was no significant increase in hospitalization or ICU  
269 admission in the co-infected cohort ([Lansbury et al., 2020](#)). Overall, the incidence of respiratory  
270 viral co-infections is low and may not be considered a key factor associated with mortality.

271 Our analysis reveals the diversity of SARS-CoV-2 in EMR and emphasizes the importance of  
272 considering temporal incidence and concurrent mutations in disease correlations. Our study is  
273 limited by the relatively low number of specimens sequenced per country spanning ten months of  
274 COVID-19 pandemic. There is a critical need for continuous and consistent surveillance of  
275 SARS-CoV-2 genomic variations in the EMR region.

276

277 **Acknowledgments**

278 S.O. is the recipient of a joint doctoral fellowship from the American University of Beirut (AUB)  
279 and the National Council for Scientific Research of Lebanon (CNRS-L). We gratefully  
280 acknowledge the authors from the originating laboratories responsible for obtaining the  
281 specimens, as well as the submitting laboratories where the genome data were generated and  
282 shared via GISAID, on which this research is based (a detailed list of authors and laboratories  
283 can be found in the supplementary material). We also thank Dr. Colin A. Smith and Dr. Heinrich  
284 zu Dohnna (Biology department, American University of Beirut) for their valuable comments.

285 **Competing Interests:** The authors declare no conflicts of interest.

286 **Funding:** This research did not receive any specific grant from funding agencies in the public,  
287 commercial, or not-for-profit sectors.

288

289 **References**

- 290 Adlhoch, C., Mook, P., Lamb, F., Ferland, L., Melidou, A., Amato-Gauci, A.J., Pebody, R. and  
291 European Influenza Surveillance, N., 2021. Very little influenza in the WHO European  
292 Region during the 2020/21 season, weeks 40 2020 to 8 2021. *Euro Surveill* 26.
- 293 Al Saidi, A.M.O., Nur, F.A., Al-Mandhari, A.S., El Rabbat, M., Hafeez, A. and Abubakar, A.,  
294 2020. Decisive leadership is a necessity in the COVID-19 response. *The Lancet* 396, 295-  
295 298.
- 296 Alm, E., Broberg, E.K., Connor, T., Hodcroft, E.B., Komissarov, A.B., Maurer-Stroh, S.,  
297 Melidou, A., Neher, R.A., O'Toole, A., Pereyaslov, D., laboratories, W.H.O.E.R.s.,  
298 group, G.E., laboratories, W.H.O.E.R.s. and group\*, G.E., 2020. Geographical and  
299 temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to  
300 June 2020. *Euro Surveill* 25.
- 301 Becerra-Flores, M. and Cardozo, T., 2020. SARS-CoV-2 viral spike G614 mutation exhibits  
302 higher case fatality rate. *Int J Clin Pract* 74, e13525.
- 303 Callaway, E., 2020. The coronavirus is mutating - does it matter? *Nature* 585, 174-177.
- 304 Daw, M.A., 2020. Corona virus infection in Syria, Libya and Yemen; an alarming devastating  
305 threat. *Travel Med Infect Dis* 37, 101652.
- 306 Eaaswarkhanth, M., Al Madhoun, A. and Al-Mulla, F., 2020. Could the D614 G substitution in  
307 the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?  
308 *International Journal of Infectious Diseases*.
- 309 Elghoudi, A., Aldhanhani, H., Ghatasheh, G., Sharif, E. and Narchi, H., 2020. Covid-19 in  
310 Children and Young Adolescents in Al Ain, United Arab Emirates- a Retrospective  
311 Cross-Sectional Study. *Front Pediatr* 8, 603741.
- 312 Fineberg, H.V., 2020. The Toll of COVID-19. *JAMA* 324, 1502-1503.
- 313 Ge, Y. and Sun, S., 2020. Estimation of Coronavirus Disease Case-Fatality Risk in Real Time.  
314 *Emerg Infect Dis* 26, 1922-1923.
- 315 GISAID, 2020. Clade and lineage nomenclature aids in genomic epidemiology studies of active  
316 hCoV-19 viruses. GISAID, Munich.
- 317 Grubaugh, N.D., Hanage, W.P. and Rasmussen, A.L., 2020. Making Sense of Mutation: What  
318 D614G Means for the COVID-19 Pandemic Remains Unclear. *Cell* 182, 794-795.
- 319 Hadfield, J., Megill, C., Bell, S.M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P.,  
320 Bedford, T. and Neher, R.A., 2018. Nextstrain: real-time tracking of pathogen evolution.  
321 *Bioinformatics* 34, 4121-4123.
- 322 Hartenian, E., Nandakumar, D., Lari, A., Ly, M., Tucker, J.M. and Glaunsinger, B.A., 2020. The  
323 molecular virology of coronaviruses. *J Biol Chem* 295, 12910-12934.
- 324 Hillen, H.S., Kokic, G., Farnung, L., Dienemann, C., Tegunov, D. and Cramer, P., 2020.  
325 Structure of replicating SARS-CoV-2 polymerase. *Nature* 584, 154-156.
- 326 Hou, Y.J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinno, K.H., 3rd, Leist, S.R.,  
327 Schafer, A., Nakajima, N., Takahashi, K., Lee, R.E., Mascenik, T.M., Graham, R.,  
328 Edwards, C.E., Tse, L.V., Okuda, K., Markmann, A.J., Bartelt, L., de Silva, A., Margolis,  
329 D.M., Boucher, R.C., Randell, S.H., Suzuki, T., Gralinski, L.E., Kawaoka, Y. and Baric,  
330 R.S., 2020. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and  
331 transmission in vivo. *Science*.
- 332 Ilmjärv, S., Abdul, F., Acosta-Gutiérrez, S., Estarellas, C., Galdadas, I., Casimir, M.,  
333 Alessandrini, M., Gervasio, F.L. and Krause, K.-H., 2020. Epidemiologically most



334 successful SARS-CoV-2 variant: concurrent mutations in RNA-dependent RNA  
 335 polymerase and spike protein. medRxiv.  
 336 Ioannidis, J.P.A., 2020a. Global perspective of COVID-19 epidemiology for a full-cycle  
 337 pandemic. *Eur J Clin Invest*, e13423.  
 338 Ioannidis, J.P.A., 2020b. Infection fatality rate of COVID-19 inferred from seroprevalence data.  
 339 *Bulletin of the World Health Organization*.  
 340 Jones, N., 2020. How COVID-19 is changing the cold and flu season. *Nature* 588, 388-390.  
 341 Kannan, S.R., Spratt, A.N., Quinn, T.P., Heng, X., Lorson, C.L., Sonnerborg, A., Byrareddy,  
 342 S.N. and Singh, K., 2020. Infectivity of SARS-CoV-2: there Is Something More than  
 343 D614G? *J Neuroimmune Pharmacol*.  
 344 Keaten, J., 2020. WHO: 10% of world's people might have had COVID-19, *Telegraph - Herald*.  
 345 Dubuque, Iowa.  
 346 Kim, D., Quinn, J., Pinsky, B., Shah, N.H. and Brown, I., 2020. Rates of Co-infection Between  
 347 SARS-CoV-2 and Other Respiratory Pathogens. *JAMA* 323, 2085-2086.  
 348 Kim, K.W., Deveson, I.W., Pang, C.N.I., Yeang, M., Naing, Z., Adikari, T., Hammond, J.M.,  
 349 Stevanovski, I., Beukers, A.G., Verich, A., Yin, S., McFarlane, D., Wilkins, M.R.,  
 350 Stelzer-Braid, S., Bull, R.A., Craig, M.E., van Hal, S.J. and Rawlinson, W.D., 2021.  
 351 Respiratory viral co-infections among SARS-CoV-2 cases confirmed by virome capture  
 352 sequencing. *Sci Rep* 11, 3934.  
 353 Korber, B., Fischer, W.M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N.,  
 354 Giorgi, E.E., Bhattacharya, T., Foley, B., Hastie, K.M., Parker, M.D., Partridge, D.G.,  
 355 Evans, C.M., Freeman, T.M., de Silva, T.I., Sheffield, C.-G.G., McDanal, C., Perez, L.G.,  
 356 Tang, H., Moon-Walker, A., Whelan, S.P., LaBranche, C.C., Saphire, E.O. and  
 357 Montefiori, D.C., 2020. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G  
 358 Increases Infectivity of the COVID-19 Virus. *Cell* 182, 812-827 e19.  
 359 Lansbury, L., Lim, B., Baskaran, V. and Lim, W.S., 2020. Co-infections in people with COVID-  
 360 19: a systematic review and meta-analysis. *J Infect* 81, 266-275.  
 361 Pachetti, M., Marini, B., Benedetti, F., Giudici, F., Mauro, E., Storici, P., Masciovecchio, C.,  
 362 Angeletti, S., Ciccozzi, M., Gallo, R.C., Zella, D. and Ippodrino, R., 2020. Emerging  
 363 SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase  
 364 variant. *J Transl Med* 18, 179.  
 365 Plante, J.A., Liu, Y., Liu, J., Xia, H., Johnson, B.A., Lokugamage, K.G., Zhang, X., Muruato,  
 366 A.E., Zou, J., Fontes-Garfias, C.R., Mirchandani, D., Scharton, D., Bilello, J.P., Ku, Z.,  
 367 An, Z., Kalveram, B., Freiberg, A.N., Menachery, V.D., Xie, X., Plante, K.S., Weaver,  
 368 S.C. and Shi, P.Y., 2020. Spike mutation D614G alters SARS-CoV-2 fitness. *Nature*.  
 369 Saddique, A., Rana, M.S., Alam, M.M., Ikram, A., Usman, M., Salman, M., Faryal, R., Massab,  
 370 U., Bokhari, H., Mian, M.S., Israr, A. and Safiullah, 2020. Emergence of co-infection of  
 371 COVID-19 and dengue: A serious public health threat. *J Infect* 81, e16-e18.  
 372 Salameh, P., 2020. COVID-19 in the Eastern Mediterranean Region: testing frequency,  
 373 cumulative cases and mortality analysis. *East Mediterr Health J* 26, 1005-1010.  
 374 Sallam, M., Ababneh, N.A., Dababseh, D., Bakri, F.G. and Mahafzah, A., 2021. Temporal  
 375 increase in D614G mutation of SARS-CoV-2 in the Middle East and North Africa.  
 376 *Heliyon* 7, e06035.  
 377 Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A. and Li, F., 2020. Cell entry  
 378 mechanisms of SARS-CoV-2. *Proc Natl Acad Sci U S A* 117, 11727-11734.

379 Shu, Y. and McCauley, J., 2017. GISAID: Global initiative on sharing all influenza data - from  
380 vision to reality. *Euro Surveill* 22.

381 Su, S., Wong, G., Shi, W., Liu, J., Lai, A.C.K., Zhou, J., Liu, W., Bi, Y. and Gao, G.F., 2016.  
382 Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. *Trends*  
383 *Microbiol* 24, 490-502.

384 Su, Y.C.F., Anderson, D.E., Young, B.E., Linster, M., Zhu, F., Jayakumar, J., Zhuang, Y.,  
385 Kalimuddin, S., Low, J.G.H., Tan, C.W., Chia, W.N., Mak, T.M., Octavia, S., Chavatte,  
386 J.M., Lee, R.T.C., Pada, S., Tan, S.Y., Sun, L., Yan, G.Z., Maurer-Stroh, S., Mendenhall,  
387 I.H., Leo, Y.S., Lye, D.C., Wang, L.F. and Smith, G.J.D., 2020. Discovery and Genomic  
388 Characterization of a 382-Nucleotide Deletion in ORF7b and ORF8 during the Early  
389 Evolution of SARS-CoV-2. *mBio* 11.

390 Thomson, E.C., Rosen, L.E., Shepherd, J.G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj,  
391 J.A., Davis, C., Piccoli, L., Pascall, D.J., Dillen, J., Lytras, S., Czudnochowski, N., Shah,  
392 R., Meury, M., Jesudason, N., De Marco, A., Li, K., Bassi, J., O'Toole, A., Pinto, D.,  
393 Colquhoun, R.M., Culap, K., Jackson, B., Zatta, F., Rambaut, A., Jaconi, S., Sreenu,  
394 V.B., Nix, J., Zhang, I., Jarrett, R.F., Glass, W.G., Beltramello, M., Nomikou, K.,  
395 Pizzuto, M., Tong, L., Cameroni, E., Croll, T.I., Johnson, N., Di Iulio, J., Wickenhagen,  
396 A., Ceschi, A., Harbison, A.M., Mair, D., Ferrari, P., Smollett, K., Sallusto, F.,  
397 Carmichael, S., Garzoni, C., Nichols, J., Galli, M., Hughes, J., Riva, A., Ho, A., Schiuma,  
398 M., Semple, M.G., Openshaw, P.J.M., Fadda, E., Baillie, J.K., Chodera, J.D.,  
399 Investigators, I.C., Consortium, C.-G.U., Rihn, S.J., Lycett, S.J., Virgin, H.W., Telenti,  
400 A., Corti, D., Robertson, D.L. and Snell, G., 2021. Circulating SARS-CoV-2 spike  
401 N439K variants maintain fitness while evading antibody-mediated immunity. *Cell* 184,  
402 1171-1187 e20.

403 Toyoshima, Y., Nemoto, K., Matsumoto, S., Nakamura, Y. and Kiyotani, K., 2020. SARS-CoV-  
404 2 genomic variations associated with mortality rate of COVID-19. *J Hum Genet*.

405 Uyeki, T.M., Santoli, J. and Jernigan, D.B., 2020. Preparing for the 2020-2021 Influenza Season.  
406 *JAMA* 324, 2318-2319.

407 van Dorp, L., Acman, M., Richard, D., Shaw, L.P., Ford, C.E., Ormond, L., Owen, C.J., Pang, J.,  
408 Tan, C.C.S., Boshier, F.A.T., Ortiz, A.T. and Balloux, F., 2020a. Emergence of genomic  
409 diversity and recurrent mutations in SARS-CoV-2. *Infect Genet Evol* 83, 104351.

410 van Dorp, L., Richard, D., Tan, C.C.S., Shaw, L.P., Acman, M. and Balloux, F., 2020b. No  
411 evidence for increased transmissibility from recurrent mutations in SARS-CoV-2. *Nat*  
412 *Commun* 11, 5986.

413 Vankadari, N., 2020. Overwhelming mutations or SNPs of SARS-CoV-2: A point of caution.  
414 *Gene* 752, 144792.

415 Volz, E., Hill, V., McCrone, J.T., Price, A., Jorgensen, D., O'Toole, A., Southgate, J., Johnson,  
416 R., Jackson, B., Nascimento, F.F., Rey, S.M., Nicholls, S.M., Colquhoun, R.M., da Silva  
417 Filipe, A., Shepherd, J., Pascall, D.J., Shah, R., Jesudason, N., Li, K., Jarrett, R.,  
418 Pacchiarini, N., Bull, M., Geidelberg, L., Siveroni, I., Consortium, C.-U., Goodfellow, I.,  
419 Loman, N.J., Pybus, O.G., Robertson, D.L., Thomson, E.C., Rambaut, A. and Connor,  
420 T.R., 2021. Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on  
421 Transmissibility and Pathogenicity. *Cell* 184, 64-75 e11.

422 Wang, C., Liu, Z., Chen, Z., Huang, X., Xu, M., He, T. and Zhang, Z., 2020. The establishment  
423 of reference sequence for SARS-CoV-2 and variation analysis. *J Med Virol* 92, 667-674.

- 424 WHO. Eastern Mediterranean Regional Office COVID-19 Dashboard (2021).  
425 <http://www.emro.who.int/index.html>. Last Accessed: Jan 22 2021.
- 426 WHO. WHO Coronavirus Disease (COVID-19) Dashboard (2021). <https://covid19.who.int/>.  
427 Last Accessed: Jan 22 2021.
- 428 WHO. WHO Global Influenza Surveillance and Response System (GISRS). Number of  
429 Specimens Positive for Influenza by Subtype, Eastern Mediterranean Region of WHO  
430 (2021) <https://apps.who.int/flumart/Default?ReportNo=3&WHORegion=> Last Accessed:  
431 Mar 21 2021.
- 432 Wilson, N., Kvalsvig, A., Barnard, L.T. and Baker, M.G., 2020. Case-Fatality Risk Estimates for  
433 COVID-19 Calculated by Using a Lag Time for Fatality. *Emerg Infect Dis* 26, 1339-  
434 1441.
- 435 Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.L., Abiona, O., Graham, B.S. and  
436 McLellan, J.S., 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion  
437 conformation. *Science* 367, 1260-1263.
- 438 Young, B.E., Fong, S.W., Chan, Y.H., Mak, T.M., Ang, L.W., Anderson, D.E., Lee, C.Y.,  
439 Amrun, S.N., Lee, B., Goh, Y.S., Su, Y.C.F., Wei, W.E., Kalimuddin, S., Chai, L.Y.A.,  
440 Pada, S., Tan, S.Y., Sun, L., Parthasarathy, P., Chen, Y.Y.C., Barkham, T., Lin, R.T.P.,  
441 Maurer-Stroh, S., Leo, Y.S., Wang, L.F., Renia, L., Lee, V.J., Smith, G.J.D., Lye, D.C.  
442 and Ng, L.F.P., 2020. Effects of a major deletion in the SARS-CoV-2 genome on the  
443 severity of infection and the inflammatory response: an observational cohort study.  
444 *Lancet* 396, 603-611.
- 445 Yurkovetskiy, L., Wang, X., Pascal, K.E., Tomkins-Tinch, C., Nyalile, T.P., Wang, Y., Baum,  
446 A., Diehl, W.E., Dauphin, A., Carbone, C., Veinotte, K., Egri, S.B., Schaffner, S.F.,  
447 Lemieux, J.E., Munro, J.B., Rafique, A., Barve, A., Sabeti, P.C., Kyratsous, C.A.,  
448 Dudkina, N.V., Shen, K. and Luban, J., 2020. Structural and Functional Analysis of the  
449 D614G SARS-CoV-2 Spike Protein Variant. *Cell* 183, 739-751 e8.
- 450 Zhang, L., Jackson, C.B., Mou, H., Ojha, A., Peng, H., Quinlan, B.D., Rangarajan, E.S., Pan, A.,  
451 Vanderheiden, A., Suthar, M.S., Li, W., Izard, T., Rader, C., Farzan, M. and Choe, H.,  
452 2020. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and  
453 infectivity. *Nat Commun* 11, 6013.
- 454 Zhou, B., Thi Nhu Thao, T., Hoffmann, D., Taddeo, A., Ebert, N., Labroussaa, F., Pohlmann, A.,  
455 King, J., Steiner, S., Kelly, J.N., Portmann, J., Halwe, N.J., Ulrich, L., Trueb, B.S., Fan,  
456 X., Hoffmann, B., Wang, L., Thomann, L., Lin, X., Stalder, H., Pozzi, B., de Brot, S.,  
457 Jiang, N., Cui, D., Hossain, J., Wilson, M., Keller, M., Stark, T.J., Barnes, J.R., Dijkman,  
458 R., Jores, J., Benarafa, C., Wentworth, D.E., Thiel, V. and Beer, M., 2021. SARS-CoV-2  
459 spike D614G change enhances replication and transmission. *Nature*.

460

461

462 **Figure Legends**

463 **Figure 1. Distribution of SARS-CoV-2 sequences in EMR countries.** (A) Pie chart showing  
464 number of available sequences as of 1 January 2021. (B) Histogram showing ratio of sequences  
465 per million population. (C) Histogram showing ratio of sequences per 10,000 confirmed cases of  
466 SARS-CoV-2. (D) Temporal distribution of sequence collection in EMR countries from January  
467 through December 2020. (E) Averages of delay in sequence submission (in days) of available  
468 EMR countries. For UAE, Saudi Arabia and Jordan, only the first and last 100 collected  
469 sequences were considered. Error bars represent standard deviation.

470 **Figure 1. Common SARS-CoV-2 substitutions detected in EMR countries.** Bar graphs  
471 showing percentages of most prevalent SARS-CoV-2 variants per country, excluding single-  
472 incidence variants. Colored are the top ten most represented substitutions; in black are country-  
473 specific ones.

474 **Figure 2. EMR sequences are dominantly distributed in G, GR and GH GISAID clades.** (A)  
475 Phylogenetic tree of GISAID clades plotted over time. Red arrow points to the introduction of  
476 S\_D614G, marking the emergence of G, GR and GH clades (reproduced from Nextstrain [Ref.  
477 17]). (B) Clade distribution of all 3345 sequences. (C) Temporal distribution of sequences as  
478 clades in the top four represented countries.

479 **Figure 4. Gender and age distribution of SARS-CoV-2 variants in four EMR countries.**  
480 Gender distribution of (A) sequences of Saudi Arabia, UAE, Oman and Egypt and (B) select top  
481 most frequent variants of these countries. (C) Age groups distribution of sequences from four  
482 EMR countries and (D) of most frequent variants. Sequences in this figure are as of 12  
483 November 2020 due to the inability to extract demographics from metafiles after this date.






484 **Figure 5. Only NSP12\_P323L of the ten most common SARS-CoV-2 single variants**  
485 **correlates with higher case fatality rates in seven EMR countries.** Scatter plots showing  
486 percentages of each of the top ten represented substitutions with cumulative CFR as of 1 January  
487 2021. R, Pearson's correlation coefficient.















488 **Figure 6. The 'D614G & P323L' double variant is predominant in select EMR countries,**  
489 **but does not correlate with increased fatality.** (A) Percentages of Wuhan-like, S\_D614G only,  
490 NSP\_P323L only and 'D614G & P323L' double variants in eight EMR countries. (B)  
491 Distribution of the 'D614 & P323L' variant based on age groups in top four represented EMR  
492 countries. (C) Scatter plots showing correlation of three variants with CFR in seven EMR  
493 countries. R, Pearson's correlation coefficient.

494 **Figure 7. Temporal distribution and fatality correlation of the 'D614G & P323L' double**  
495 **variant with CFR in each of the top four represented EMR Countries.** (A) Time-based  
496 evolution of double variant percentages and CFR in Saudi Arabia, UAE, Oman and Egypt. (B)  
497 Scatter plots showing correlations of the 'D614G & P323L' double variant with CFR over select  
498 months of pandemic life in the top four represented EMR countries. R, Pearson's correlation  
499 coefficient.

500 **Supplementary Figure 1. Genome length of available EMR sequences.** Sequence size  
501 distribution (%) of available EMR sequences in two categories: <5000 bp and >25000 bp.





502 **Supplementary Figure 2. Correlation between the ‘D614G & P323L’ double variant with**  
503 **CFR over eight months of the pandemic.** Scatter plots showing cumulative percentages of the  
504 double variant in seven EMR countries versus respective CFR as of the end of each month,  
505 March through September and November. R, Pearson’s correlation coefficient.











**A****Sequence Count per Country****B****C****D****E**















**S\_D614G****NSP12\_P323L****NS3\_Q57H****N\_R203K****N\_G204R****N\_S194L****NSP6\_L37F****NSP2\_V198I****NS8\_L84S****N\_S202N**

**A****B****C****P323L only****D614G & P323L**

**A****B**